Today, crizotinib must be regarded as a well-established therapy in NSCLC patients with ALK or ROS1 rearrangement, but when it comes to patients with MET dysregulations, the documentation is less convincing, and a regulatory approval for this indication has not yet been granted. This evidence concerns the gene MET and non-small cell lung carcinoma.